These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA Blood Cancer J; 2021 Aug; 11(8):138. PubMed ID: 34341335 [TBL] [Abstract][Full Text] [Related]
8. Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination. Gung C; McGuire R; George M; Abdulkareem A; Belden KA; Porcu P; Martinez-Outschoorn U; Binder AF; Chervenova I; Alpdogan O Front Oncol; 2022; 12():840451. PubMed ID: 35875166 [TBL] [Abstract][Full Text] [Related]
9. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Funakoshi Y; Yakushijin K; Ohji G; Hojo W; Sakai H; Watanabe M; Kitao A; Miyata Y; Saito Y; Kawamoto S; Yamamoto K; Ito M; Koyama T; Imamura Y; Kiyota N; Matsuoka H; Mori Y; Minami H Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746573 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study. Wirth SRM; Podar K; Pecherstorfer M; Wohlfarth P; Jaeger U; Singer J Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672473 [TBL] [Abstract][Full Text] [Related]
11. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. Jangra S; Ye C; Rathnasinghe R; Stadlbauer D; ; Krammer F; Simon V; Martinez-Sobrido L; García-Sastre A; Schotsaert M medRxiv; 2021 Jan; ():. PubMed ID: 33532796 [TBL] [Abstract][Full Text] [Related]
12. Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2. Fattizzo B; Rampi N; Barcellini W Blood Rev; 2023 Jul; 60():101077. PubMed ID: 37029066 [TBL] [Abstract][Full Text] [Related]
13. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065 [TBL] [Abstract][Full Text] [Related]
14. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Jahn M; Korth J; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Tyczynski B; Gäckler A; Witzke O; Dittmer U; Dolff S; Wilde B; Kribben A Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33918085 [TBL] [Abstract][Full Text] [Related]
15. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer. Mueller T Clin Chim Acta; 2021 Jul; 518():9-16. PubMed ID: 33741357 [TBL] [Abstract][Full Text] [Related]
16. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. Jackson LA; Anderson EJ; Rouphael NG; Roberts PC; Makhene M; Coler RN; McCullough MP; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott A; Flach B; Doria-Rose NA; Corbett KS; Morabito KM; O'Dell S; Schmidt SD; Swanson PA; Padilla M; Mascola JR; Neuzil KM; Bennett H; Sun W; Peters E; Makowski M; Albert J; Cross K; Buchanan W; Pikaart-Tautges R; Ledgerwood JE; Graham BS; Beigel JH; N Engl J Med; 2020 Nov; 383(20):1920-1931. PubMed ID: 32663912 [TBL] [Abstract][Full Text] [Related]
17. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303 [TBL] [Abstract][Full Text] [Related]
18. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis]. Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494 [TBL] [Abstract][Full Text] [Related]
19. Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. Hedges JF; Thompson MA; Snyder DT; Robison A; Taylor MP; Jutila MA Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34199357 [TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? Lippi G; Henry BM; Plebani M Diagnostics (Basel); 2021 May; 11(6):. PubMed ID: 34070341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]